Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grassley reasserts S 1002

This article was originally published in The Gray Sheet

Executive Summary

In a June 7 "Dear Colleague" letter, Senate Finance Committee Chair Chuck Grassley (R-Iowa) responds to a recent Republican Policy Committee paper advising against extension of the physician-owned specialty hospital moratorium by emphasizing his "Hospital Fair Competition Act of 2005," which would allow gainsharing arrangements in lieu of physician self-referral (1"The Gray Sheet" May 16, 2005, p. 6). While revision of the DRG payment system has been viewed as a viable solution to anticompetitive practices within the specialty hospital realm, Grassley claims such changes "alone are not enough." S 1002 would "level the playing field to allow for true competition," he says...

You may also be interested in...



Gainsharing Could Gain Momentum Under Senate’s Specialty Hospital Bill

Gainsharing arrangements between hospitals and physicians to foster improved efficiency would be allowed under "The Hospital Fair Competition Act of 2005" (S 1002), introduced May 11

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel